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INTRODUCTION 
 
Metabolic syndrome is a constellation of interrelated risk factors of metabolic 
origin – metabolic risk factors – that appear to directly promote the 
development of atherosclerotic cardio vascular disease and type 2 diabetes 
mellitus by two to three fold8. 
It has variously been referred as the insulin resistance syndrome.  Insulin 
resistance is the key pathologic feature of the syndrome, since its components 
are either causes or consequences of impaired insulin action. 
The constellation of dyslipidemia 
(hypertriglyceridemia and low levels of high-
density lipoprotein cholesterol), elevated blood 
pressure, impaired glucose tolerance, and 
central obesity is identified now as metabolic 
syndrome.It is also a prothrombotic and 
proinflammatory state.  
Soon, metabolic syndrome will overtake 
cigarette smoking as the number one risk factor 
for heart disease . The National Cholesterol 
Education Program1-Adult Treatment Panel III 
has identified metabolic syndrome as an 
indication for vigorous lifestyle intervention. 
Studies based on populations at high risk for cardiovascular disease have 
shown a very high prevalence of metabolic syndrome. 
 In this study the prevalence of metabolic syndrome in acute myocardial 
infarction  and its impact on hospital outcomes like heart failure, length of 
ICCU stay, case fatality have been studied.  The relative influence of each of 
the 5 components of NCEP ATP III definition of metabolic syndrome on 
various hospital outcomes like risk of death and heart failure was also studied. 
In this study, metabolic syndrome was defined according to the criteria of the 
National Cholesterol Education Program’s Adult Treatment Panel III (NCEP-
ATP III). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
 
1. To ascertain the prevalence of metabolic syndrome in acute myocardial infarction 
patients  
 2. To study the impact of metabolic syndrome on hospital outcomes, in particular, 
death and heart failure in acute myocardial infarction patients  
 
3. To assess the relative influence of each of the 5 components of NCEP ATP 
III definition of metabolic syndrome on the risk of death and heart failure 
 
4. To identify and treat the components of metabolic syndrome in acute 
myocardial infarction patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
 
A report1 from the National Cholesterol Education Program- Adult Treatment 
Panel (NCEP-ATP III) identified metabolic syndrome as an independent risk 
factor for cardiovascular disease and considered it an indication for intensive 
lifestyle modification. 
The predominant underlying risk factors for the syndrome appear to be 
abdominal obesity and insulin resistance5,6other associated conditions can be 
physical inactivity,3,7aging,8 and hormonal imbalance. 
Metabolic syndrome can lead to serious medical 
problems, including type 2  
 
diabetes, high blood pressure, heart disease and 
stroke. 
 
Other associated diseases are: 
Fatty liver  
Non-alcoholic steatohepatitis  
Acanthosis nigricans  
Hemochromatosis  
Polycystic ovarian syndrome 
Several recent reports 25, 26, 27, 28 indicate that the presence of the metabolic 
syndrome is associated with increased risk for both ASCVD and type 2 
diabetes. Persons with the metabolic syndrome have at least a 2-fold increase in 
risk for ASCVD9, compared with those without metabolic syndrome. Risk for 
type 2 diabetes in both men and women is increased about 5-fold 9. The risk for 
diabetes is highest in those with impaired fasting glucose or IGT. 
 
 Other metabolic abnormalities that are  associated with this syndrome are 
obesity, microalbuminuria, and abnormalities in fibrinolysis and coagulation 13–
16. In 1998, WHO3 proposed a unifying definition for the syndrome and chose to 
call it the metabolic syndrome rather than the insulin resistance syndrome 17. 
This name was chosen primarily because it was not established that insulin 
resistance was the cause of all the components of the syndrome.  
Nomenclature 
Other names for metabolic syndrome,100   are 
Syndrome X101 
Metabolic syndrome X 
Plurimetabolic syndrome 
Insulin resistance syndrome103,104 
"deadly quartet,"102 
hypertriglyceridemic waist.105 
Reaven's Syndrome 
CHAOS (Australia) 
Wohlstandssyndrom (German). 
 
 
 
 
 
 
 
History 
 
The term "metabolic syndrome" dates back to at least the late 1950's, but came 
into common usage in the late 1970's to describe various associations of risk 
factors with diabetes. 
Multiple cardiovascular risk factors of endogenous origin commonly aggregate 
in one individual. This aggregation was originally observed many years ago10,19 
. 
The history of metabolic syndrome dates back to postmortem descriptions by 
Morgagni18 of both atherosclerosis and visceral obesity in noble persons whose 
lifestyle was characterized by “literary studies, sedentary life-style and 
abundant meals” 
In 1988, Stanford University endocrinologist Dr. Gerald Reaven8, in his 
Banting lecture, named after Sir Frederick Banting,  reintroduced the concept 
of syndrome X for the clustering of cardiovascular risk factors like 
hypertension, glucose intolerance, high triglycerides, and low HDL cholesterol 
concentrations. Reaven did not include abdominal obesity, which has also been 
hypothesized as the underlying factor, as part of the condition. 
The syndrome is, however, much older, having been already observed in 1923 
by Kylin, who described the clustering of hypertension, hyperglycemia, and 
gout as a syndrome 10 
The Marseilles physician, Dr. Jean Vague19,20 made the interesting observation 
that upper body obesity appeared to predispose to diabetes, atherosclerosis, 
gout, and calculi. He classified obesity into  those with “gynoid” and those with 
“android” obesity. 
Avogaro, Crepaldi and co-workers described six moderately obese patients 
with diabetes, hypercholesterolemia, and marked hypertriglyceridemia all of 
which improved when the patients were put on a hypocaloric, low carbohydrate 
diet. 
In 1977, Haller used the term “metabolic syndrome” for associations of obesity, 
diabetes mellitus, hyperlipoproteinemia, hyperuricemia and steatosis hepatitis 
when describing the additive effects of risk factors on atherosclerosis. 
The same year, Singer used the term for associations of obesity, gout, diabetes 
mellitus, and hypertension with hyperlipoprotenemia 
 
Epidemiology and prevalence 
 
 Metabolic syndrome  is prevalent  in 25% using WHO3 and 24% using ATP1 
III definitions in individuals aged 20 years2 or above.the prevalence is  equal 
among both the sexes.  In-patients with diabetes the prevalence was 86%. 
The prevalence of metabolic syndrome in coronary artery disease is 51% and 
the number of its metabolic features increases with the severity of angiographic 
coronary artery disease21. 
The prevalence of metabolic syndrome ranges from 35% to 80% in patients with 
hypertension or type 2 diabetes melliltus22,25. 
It is also associated with an increase in mean carotid intima media thickness and 
decrease in ankle brachial pressure index. The prevalence of metabolic syndrome 
correlated with the extent of vascular damage23. 
 
 
Definitions of Metabolic syndrome 
 
 
There are various definitions for metabolic syndrome. The widely used definitions are  
 
 
 
I. WORLD HEALTH ORGANISATION (WHO)3 
 
Clinical Measure                                  WHO (1988)                        
 
Insulin resistance                   IGT,IFT,T2DM, or lowered              
                                               Insulin sensitivity plus 
                                               Any 2 of the following 
 
Body weight                          Men: waist to hip ratio>0.90            
                                               Women: waist to hip ratio>0.85 
                                               And/ or BMI>30 kg/ sq. m 
 
Lipid                                      TG >=150 mg/dL 
                                               HDL cholesterol <40 mg/dL for men,  
                                                                           <50 mg/dL for women                                             
 
Blood pressure                       >=140/90 mmHg. 
 
Glucose                                 IGT,IFG or T2DM 
 
OTHER                                microalbuminuria (Urinary albumin to 
creatinine                            
                                             ratio: 30 mg per g, or albumin excretion rate: 20 
mcg          
                                             per minute)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II. INTERNATIONAL DIABETIC FEDERATION12             
 
    
Clinical Measure                                IDF (2005) 
 
Insulin resistance                           None                                         
               
 
Body weight                                  Increased waist circumference(population  
                                                        specific) 
                                                       Plus any 2 of the following 
 
Lipid                                              TG >=150 mg/dL or on R/ 
                                                       HDL cholesterol <40 mg/dL for men,  
                                                      <50 mg/dL for women or on R/ 
 
Blood pressure                              >=130/85 mmHg or on R/ 
 
Glucose                                         >=100 mg/dL(including diabetes) 
 
 
III. THE ADULT TREATMENT PANEL1 III OF THE  
      NATIONAL CHOLESTEROL EDUCATION PROGRAM (2001, 2005) 
It defined the diagnosis as three or more of the following five 
1. Increased waist circumference (>=102 cm in men and >=88 cm in 
women) 
2. Elevated triglycerides (>=150 mg/dL or 1.7 mmol/l) 
3. Decreased HDL cholesterol (<40 mg/dL for men, <50 mg/dL for women) 
4. Blood pressure above 130/85 or active treatment for hypertension 
5. Glucose levels above 100 mg/dL or active treatment for hyperglycemia 
 
 
 
 
 
 
IV.  AMERICAN HEART ASSOCIATION ,   
       NATAIONAL HEART , LUNG AND BLOOD INSTITUTE9, JULY 2005 
       SCIENTIFIC STATEMENT 
 
Metabolic syndrome was defined according to the AHA/NHLBI statement 
maintaining NCEP ATP III1 criteria with minor modifications. Patients 
received a diagnosis of metabolic syndrome if they had any 3 of the following 
5 criteria: 
1. Abdominal obesity (waist circumference men >102 cm and in women >88 
cm for western population and > 90 cm in men and > 80 cm in women of 
Asian origin) 
2. High triglyceride levels >=150mg/dL 
3. Low HDL Cholesterol level <40 mg/dL in men and <50 mg/dL in women 
4. High blood pressure (treated hypertension, systolic blood pressure >=130 
mm Hg, or diastolic blood pressure >= 85 mm Hg) 
5. Fasting glucose >= 100 mg/dL or on treatment for diabetes mellitus 
In accordance with a 2003 recommendation from the American Diabetes 
Association11, in the last three definitions of IDF, Adult Treatment Panel III of 
the National Cholesterol Education Program (2001, 2005) and AHA/NHLBI 
statement the value of impaired fasting glucose was reduced from 110 mg/dL 
to 100 mg/dL. 
When the waist circumference is 90 cm or more in men or 80 cm or more in 
women, the term abdominal obesity can be applied. The advantage of 
measuring waist circumference is that an excess abdominal fat is correlated 
more closely with the presence of metabolic risk factors than total body fat.  
GENETICS 
 
A "thrifty genotype hypothesis" implicates the evolutionary selection of 
metabolic genes in the development of the metabolic syndrome in the setting of 
a modern environment of physical inactivity and dietary excess.  Family studies 
suggest a complex but significant genetic basis to individual components of the 
metabolic syndrome. However, identifying a genetic profile that defines an 
increased risk of developing a complex disease trait, such as the metabolic 
syndrome or atherosclerosis, remains difficult. 
 
PATHOPHYSIOLOGY -MECHANISTIC LINKS BETWEEN 
COMPONENTS 
 
INSULIN RESISTANCE 
        Insulin resistance per se is independently atherogenic. Insulin resistance is 
the 
pathophysiological process underlying the clustering of cardiovascular risk 
factors in the metabolic syndrome.2,31 . In prospective studies, the presence of 
insulin resistance is associated with increased ASCVD risk 40.  
 Some of the risk factors that are hallmarks of insulin resistance—for example, 
abnormal lipid levels, glucose intolerance, and high blood insulin levels—
appear to provide a fertile ground for the development of serious chronic 
diseases such as diabetes, heart disease, and fatty liver. For instance, high blood 
insulin levels have been linked to hypertension, while insulin resistance appears 
to promote atherosclerosis. 
Multiple metabolic pathways have been proposed to link insulin resistance and 
compensatory hyperinsulinemia to the other metabolic risk factors31,32. This is 
true for many individuals of South Asian ethnicity.33,34. Although insulin-
resistant individuals need not be clinically obese, they have an abnormal fat 
distribution that is characterized by predominant upper body fat. 
Asymmetric dimethylarginine (ADMA), a naturally occurring substance, is increased 
in metabolic syndrome .  It inhibits the synthesis of nitric oxide, a potent dilator of 
blood vessels. ADMA also increases the binding of white blood cells to the 
endothelial lining of arteries, which may contribute to atherosclerosis. 
Indices of insulin resistance predict atherosclerosis and cardiovascular events 
independent of other risk factors including fasting glucose and lipid levels35. 
Many subjects with normal fasting glucose levels have insulin resistance.2The 
hyperinsulinemic clamp is considered the gold standard to define insulin 
sensitivity but requires prolonged insulin infusion and repeated blood sampling. 
Surrogate measures of insulin sensitivity, including the Homeostasis Model 
Assessment (HOMA) and Quantitative Insulin Sensitivity Check Index 
(QUICKI), have been developed that can be applied to single measurements of 
fasting insulin and glucose. These surrogates are useful in defining the MetSyn 
and in predicting the development of cardiovascular disease and type 2 diabetes 
mellitus35,37. 
Insulin resistance is thought to contribute to the accumulation of fatty deposits 
in the liver. Insulin resistance also has been implicated in polycystic ovary 
syndrome 54and nonalcoholic steatohepatitis (NASH). 
Innate immunity and inflammation play a role in the development of insulin 
resistance and predict the development of type 2diabetes mellitus38,39. Thus, the 
pathophysiology of insulin resistance and atherosclerotic cardiovascular events 
may have a common proximal inflammatory basis. 
DYSGLYCEMIA 
In cross-sectional and prospective studies, fasting and postprandial  glucose and 
insulin concentrations are positively correlated.  The increase in insulin 
concentrations is paralleled by a decrease in insulin sensitivity. Decreased 
insulin sensitivity leads to defects in the ability of insulin to inhibit hepatic 
glucose production and to stimulate glucose uptake in peripheral tissues and 
thereby leading to hyperglycemia. 
 Increased FFA concentrations and resistance to the antilipolytic effect of insulin may 
contribute to worsening of hyperglycemia41 because of multiple interactions between 
FFA and glucose metabolism both in the liver and in skeletal muscle. 
A variety of mechanisms  to explain how elevated plasma glucose may promote 
atherosclerosis are postulated42. 
A variety of mechanisms have been proposed whereby hyperglycemia might 
promote atherosclerosis 42. Examples include nonenzymatic glycosylation of 
lipids and proteins, pathogenic effects of advanced glycation products, 
increased oxidative stress, activation of protein kinase C, and microvascular 
disease of the vasa vasorum of the coronary arteries.  
OBESITY AND ABDOMINAL OBESITY 
 
Obesity is related to insulin resistance43,44  Obesity is associated with impaired insulin 
stimulation of glucose uptake and defect in the ability of insulin to inhibit endogenous 
glucose production and lipolysis in adipose tissue.  These defects appear more severe 
in individuals with android (abdominal fat distribution) as compared to gynoid 
obesity.  
Upper-body obesity correlates strongly with insulin resistance. Excess visceral 
fat is  strongly associated with insulin resistance24,35,36,37.Excess subcutaneous 
abdominal (or truncal) fat also carries a significant association with insulin 
resistance.45-50An interesting feature of upper-body obesity is a high release of 
nonesterified fatty acids61 from adipose tissue51; this contributes to 
accumulation of lipid in sites other than adipose tissue. Ectopic lipid 
accumulation in muscle and liver seemingly predisposes to insulin resistance52 
and dyslipidemia53. 
The foremost physical consequence of obesity is atherosclerotic cardiovascular 
disease (ASCVD) 1,9 . The majority of obese persons who develop ASCVD typically 
have metabolic syndrome.  
Body mass index is a relatively insensitive indicator  for metabolic and cardiovascular 
complications of obesity, as compared with measures of central or abdominal 
adiposity.54 Waist circumference reflects both abdominal subcutaneous adipose tissue 
(SAT) and abdominal visceral adipose tissue (VAT) and is a general index of central 
(trunk) fat mass. So, waist circumference is preferred for measuring abdominal 
obesity. VAT has been proposed as the major determinant of metabolic and 
cardiovascular complications of obesity55. 
Our understanding of the relation between obesity and metabolic risk factors is 
growing rapidly. This understanding is based on the discovery of multiple products 
released from adipocytes60.  
Nonesterified fatty acids (NEFAs)  
Inflammatory cytokines  
PAI-1  
Adiponectin  
Leptin  
Resistin   
Circulating cytokines have systemic effects, i.e. promoting insulin resistance in 
muscle 63, increased synthesis of acute-phase reactants in the liver (CRP and 
fibrinogen), or activation of macrophages in atheromatous plaques 68.   
 Excessive influx of NEFAs into muscle leads to insulin resistance. Randle et 
al62 postulated that excess fatty acids in muscle inhibit glucose oxidation 
(glucose-fatty acid cycle). Recent research 63suggests that muscle levels of 
diacylglycerol are raised, which stimulates the serine phosphorylation of the 
insulin receptors and thereby inhibits normal insulin signaling. Other 
mechanisms also may play a role   in insulin resistance in muscle64.  
Fat accumulation in the liver seemingly produces insulin resistance as it does in 
muscle. Reduction in insulin action in liver allows for enhanced 
gluconeogenesis and increased hepatic glucose output.  
Hypotheses have been developed to link higher NEFA levels to higher blood 
pressures 66. Accumulation of fat in the liver has been reported to be associated 
with increased hepatic synthesis of PAI-1, fibrinogen, and inflammatory 
cytokines, the key mediators of the prothrombotic and proinflammatory states 
67.  
Adipose tissue synthesizes PAI-1. A fatty liver may be another source of PAI-1. 
The resulting high PAI-1 levels in obese persons together with the high plasma 
fibrinogen observed in such persons contributes to a prothrombotic state.  
Adiponectin59 is reported to have antiinflammatory and antiatherogenic 
properties. Obese persons generally have low levels of adiponectin and hence 
may be deprived of its protective effects against the metabolic syndrome. 
 Leptin also may play a systemic role beyond being an adipose tissue-derived 
appetite suppressant. This hormone has been reported to have a beneficial effect 
on the liver to protect against fatty liver 57,58. Its mechanism may be to enhance 
fatty acid oxidation in the liver. Finally, resistin is an adipose tissue-derived 
hormone that seemingly opposes the action of insulin 56.  
DYSLIPIDEMIA 
Dyslipidemia is a hallmark of the metabolic syndrome and is characterized by 
elevated triglycerides (TG) and low levels of HDL-C45,46. Increased fat in the 
liver provides a stimulus for increased formation and secretion of very LDL 
(VLDL) particles. The result is higher serum levels of triglyceride, apo B, and 
small LDL particles. High serum triglycerides reduce HDL-cholesterol 
concentrations through exchange of VLDL triglycerides with HDL cholesterol 
esters.  
HYPERTRIGLYCERIDEMIA  
Influx of excess NEFAs into the liver increases the triglyceride content of the 
liver (fatty liver) 65. Increased flux of free fatty acids from the periphery to the 
liver in the insulin-resistant state drives hepatic TG synthesis, which in turn 
promotes the assembly and secretion of TG-containing VLDL46. 
Insulin normally suppresses the production of VLDL particles from the liver by 
directly inhibiting the assembly and production of VLDL particles69. In insulin 
resistance this action of Insulin is lost leading to increase in serum triglycerides70. 
Under hypertriglyceridemic conditions, there is excessive exchange of cholesterol 
esters and triglyceride-rich lipoproteins, mediated by cholesterol ester transfer protein. 
 
LOW HDL CHOLESTEROL 
 
Metabolic syndrome is associated with low HDL cholesterol. HDL particles become 
enriched with triglycerides71 and act as good substrate for hepatic lipase which now 
removes HDL particles at an accelerated rate. This is mediated by mediated by the 
cholesteryl ester transfer protein.45,46 Subnormal activity of lipoprotein lipase may 
further decrease level of HDL cholesterol. 
Activation of innate immunity offers a potential unifying pathophysiology for 
insulin resistance and dyslipidemia in the metabolic syndrome. In animal 
models, activation of innate immunity leads to changes in lipoproteins, 
enzymes, transfer proteins, and receptors with an increase in atherogenic 
lipoprotein particles.47. One possible contributor to the changes in HDL during 
inflammation is the increased production of lipases that act on HDL 
phospholipids, thus reducing the lipid content of HDL and promoting its 
catabolism.48 . 
A low HDL level is another characteristic of atherogenic dyslipidemia 1. As a risk 
predictor, a low HDL rivals an elevated total apo B (or VLDL+LDL cholesterol). This 
fact has led to the concept that HDL is intimately involved in the atherogenic process. 
The theories abound as to the mechanisms whereby HDL is antiatherogenic are 
enhanced reverse cholesterol transport, antiinflammatory properties, ability to protect 
against LDL modification. Although HDL in fact may be directly antiatherogenic, it 
also is a marker for the presence of other lipid and nonlipid risk factors. 
SMALL DENSE LDL PARTICLES 
 
In metabolic syndrome LDL particles are smaller and denser than normal45,46.  
Small dense LDL particles are known to be highly atherogenic73 and provide a 
plausible link between insulin resistance and cardiovascular disease. 
The increase in the triglyceride content of LDL particles72  makes them a better 
substrate for hepatic lipase which hydrolyzes triglycerides in the LDL particles and so 
decrease their size. 
High  levels of circulating oxidised LDL, which is increased in metabolic syndrome 
are associated with a greater disposition to atherothrombotic coronary disease74.  
A theory widely held is that smaller LDL particles are more atherogenic than 
larger  
LDLs 75. Small LDL particles are a surrogate for an increased LDL particle 
number 76.  
A simple strategy for assessing the sum of atherogenic particles is measurement 
of either LDL+VLDL cholesterol (non-HDL cholesterol) or total apo B . In 
persons with metabolic syndrome, both LDL+VLDL cholesterol and total apo 
B typically are elevated. These measurements should be used increasingly both 
in risk assessment and as targets of therapy in persons with the metabolic 
syndrome 77. 
HYPERTENSION 
The association between insulin resistance and hypertension is perhaps the 
most controversial. In insulin resistant patients with essential hypertension, 
basal intracellular calcium levels have been shown to be elevated and the 
normal ability of  insulin to attenuate angiotensin II induced increases in 
intracellular calcium is blunted in skin fibroblasts78. 
The renal action of insulin to reabsorb sodium is similar in normo- and hypertensive 
insulin-resistant subjects. Such a preserved action of insulin could contribute to an 
increase  in blood pressure in hyperinsulinemic subjects79. 
Insulin resistance has consistently been found to correlate with high sodium-lithium 
counter-transport in erythrocyte membranes: this is thought to parallel increased 
activity of the sodium hydrogen ion pump in the cell membrane of other tissues, 
which could raise intracellular sodium and calcium concentrations and enhance 
vascular muscle contractility. Such action could also contribute to the development of 
hypertension in non-diabetic, insulin resistant subjects. 
A higher blood pressure is a strong risk factor for cardiovascular disease (CVD) 80. 
Well-known complication of hypertension are CHD, stroke, left ventricular 
hypertrophy, heart failure, and chronic renal failure. hypertension is particularly 
dangerous to the cardiovascular system. This concept supported by the Framingham 
Heart Study 81.  
 
Hyperuricemia 
 
Within the non-diabetic range of glucose tolerance, serum uric acid concentrations are 
positively correlated  with glucose and insulin concentrations and inversely with 
insulin resistance82. 
In normal subjects, insulin acutely reduces the renal clearance of both sodium and uric 
acid87. These actions are preserved in insulin resistant states such as obesity, diabetes 
and essential hypertension and so provide a potential mechanistic link for the 
clustering of insulin resistance with hyperuricemia83. 
 
ALTERATIONS IN COAGULATION, FIBRINOLYSIS AND PLATELET 
FUNCTION 
 
Metabolic syndrome is associated with a proinflammatory/prothrombotic state that 
includes elevated levels of C-reactive protein, endothelial dysfunction, 
hyperfibrinogenemia, increased platelet aggregation, increased levels of plasminogen 
activator inhibitor 1, elevated uric acid levels, microalbuminuria 
Pro-coagulant changes such as impaired fibrinolysis and increased levels of PAI-I and 
defects in platelets function are frequently associated with insulin resistance. 
PAI-I, an inhibitor of fibrinolysis, is elevated in obesity associated insulin 
resistance84. 
Coagulation and fibrinolytic abnormalities cause endothelial dysfunction,which in 
turn is involved in the atherogenic process 90. 
 
CHANGES IN INFLAMMATORY MARKERS  
 
IL-6 , the main regulator of the synthesis of C-reactive protein in the liver85 is 
increased in metabolic syndrome. Upto one third of circulating IL-6  originate from 
subcutaneous and visceral adipose tissue depots and circulating levels are increased in 
obese subjects86.Recently, this syndrome has been noted to be associated with a state 
of chronic, low-grade inflammation.88,89.   It is of interest that obese persons 91and 
particularly those with the metabolic syndrome 92 also have elevated levels of CRP. 
 
MICROALBUMINURIA 
 
The mechanisms underlying the clustering of  insulin resistance and microalbuminuria 
are poorly understood.  Insulin has been shown to increase urinary excretion of 
albumin and protein markers of proximal tubular function in diabetic  patients but not 
in nondiabetic individuals93.Microalbuminuria may also be a sign of preclinical 
endothelial or vascular damage94. 
 
ABNORMALITIES IN THE AUTONOMIC NERVOUS SYSTEM 
 
In insulin resistant subjects, insulin can enter the hypothalamus and other parts 
of the brain, where insulin receptors are expressed at high levels, and it acts 
centrally to stimulate the SNS95. Insulin also regulates the autonomic control of 
heart rate by decreasing vagal tone, and increasing sympathetic drive96. 
ACUTE MYOCARDIAL INFARCTION AND METABOLIC SYNDROME 
 
In prospective epidemiologic studies, hyperinsulinemia is an independent risk factor 
for CHD  in  non-diabetic men after adjusting for body weight,blood pressure and 
dyslipidemia97.This study reveals that patients with an AMI and no previous diagnosis 
of diabetes have a high prevalence of insulin resistance108 . There has been consistent 
relationship of  metabolic syndrome with prevalent MI and stroke109 
In men participating in the West of Scotland Coronary prevention Study40, the insulin 
resistance syndrome defined according to NCEP criteria  increased the risk for a CHD 
event by 1.76 fold. Men with four to five features of the syndrome had a 3.7 fold 
increase in risk for CHD. 
OTHER MARKERS OF METABOLIC SYNDROME AS PREDICTORS OF 
CARDIOVASCULAR DISEASE 
 
C-reactive protein has predicted cardiovascular disease independent of other risk 
factors98.Hyperuricemia is associated with increased mortality from all causes of 
cardiovascular disease in the NHANES I2 epidemiologic survey in women but not in 
men99.PAI-I has been found predictive for cardiovascular disease in several studies106. 
Microalbuminuria increased the relative risk of CHD  death eightfold and of all CHD 
events threefold even after adjusting for gender, smoking, blood pressure and HDL 
cholesterol107. 
All these predictors of  cardiovascular disease namely CRP, hyperuricemia, PAI-I and 
microalbuminuria are strongly associated with metabolic syndrome. 
 
 
MANAGEMENT OF METABOLIC SYNDROME 
Metabolic syndrome is the secondary target for reducing cardiovascular events. 
Smoking cessation, lowering the levels of LDL-C, and blood pressure management 
are primary target for risk reduction. Lifestyle modifications are the initial therapies 
recommended for treatment of metabolic syndrome. If lifestyle change is not 
sufficient, then drug therapies may be indicated. To date, there is insufficient evidence 
for primary use of  drugs that target the underlying causes of metabolic syndrome. 
 
 
  
 
 
 
 
 
 
SUBJECTS AND METHODS 
STUDY POPULATION 
Patients admitted with acute myocardial infarction in Intensive Coronary 
Care unit in Government Stanley Hospital, between February, 2005 and 
February, 2006 constitute the study population. A total of 85 patients were 
studied. Patients were initially studied when they were in ICCU and they were 
followed up till their discharge. They were examined and investigated 
personally. The detailed clinical study was made as per proforma. The 
emphasis of this study is mainly to ascertain the prevalence of metabolic 
syndrome in acute MI patients and to study the impact of metabolic syndrome 
on hospital outcomes especially heart failure. The relatively influence of each 
of the components of metabolic syndrome was analysed. .  No patient had been 
counted twice if he or she got admitted again after discharge during the period.   
 
INCLUSION CRITERIA 
1. Patients admitted with acute ST elevation MI  in ICCU 
2. All age groups were included 
3. Both sexes were included 
EXCLUSION CRITERIA 
Patients with non- STEMI, unstable angina were excluded. 
DIAGNOSIS OF ACUTE MYOCARDIAL INFARCTION: 
Acute STEMI was diagnosed based on typical chest pain, ECG showing ST 
elevation or new onset or suspected left bundle branch block as defined by the 
Joint Committee of the European Society of Cardiology and the American 
College of Cardiology110 
DIAGNOSIS OF METABOLIC SYNDROME 
Metabolic syndrome was defined according to the AHA/NHLBI9 statement 
maintaining NCEP ATP III1 criteria with minor modifications. Patients 
received a diagnosis of metabolic syndrome if they had any 3 of the following 
5 criteria: 
1.Abdominal obesity (waist circumference > 90 cm in men and > 80 cm in    
women9) 
2. High triglyceride levels >=150mg/dL 
3. Low HDL Cholesterol level <40 mg/dL in men and <50 mg/dL in women 
4. High blood pressure (treated hypertension, systolic blood pressure >=130 
mm Hg, or diastolic blood pressure >= 85 mm Hg) 
5. Fasting glucose >= 100 mg/dL or on treatment for diabetes mellitus 
DATA COLLECTION 
Informed consent was obtained from all patients who fit in the inclusion 
criteria. 
A detailed history was taken.  The onset, duration, character, radiation of  
chestpain were taken. Past history of CAHD, diabetes, hypertension, 
dyslipidemia, smoking, alcoholism  were taken. Special emphasis was given to 
family history of CAHD. Family history of coronary artery disease was defined 
by a history of premature coronary artery disease in first degree relatives 
(having occured in those relatives at age < 55 years for men and <65 years for 
women). Data concerning long term therapy before admission including 
aspirin, beta blockers, angiotensin converting enzyme inhibitors and statins 
were also collected.  
Body height and weight were measured. Waist circumference was measured on 
admission midway between the last rib and iliac crest and the average of 2 
measures was recorded to the nearest 0.1 cm111.  
A complete examination was done, looking for anemia, jaundice, cyanosis, 
clubbing, oedema and lymphadenopathy. Vital parameters, namely, 
temperature, respiratory rate, Pulse rate, blood pressure were recorded  
Electrocardiogram was taken at the time of admission and subsequent ECGs 
were taken as required. Acute STEMI was diagnosed based on typical chest 
pain , ECG showing ST elevation or new onset or suspected left bundle branch 
block. 
 The blood pressure values used in the study were those collected on the day 
before discharge. For the patients who died, the value recorded on the eve of 
death was used. JNC 780 was applied for staging blood pressure. At each 
participating site, echocardiography was performed on day and all ECHO 
parameters were studied including wall motion abnormalities, LVEF etc.,  
 
DEFINITION OF HEART FAILURE 
Heart failure was defined as the highest killip class127 reached during 
hospitalisation. Severe heart failure was defined as killip class greater than II..  
Cardiogenic shock was defined as a systolic blood pressure less than 90 mm Hg 
persisting for longer than 1 hour despite fluid challenge and associated with 
clinical signs of hypoperfusion125. Features of heart failure were looked for and 
killips classification was done. 
During the hospital stay, data regarding ventricular arrhythmia (ventricular 
tachycardia or fibrillation), stroke, recurrent MI, cardiogenic shock and death 
were collected. 
Patients who had one exclusion criteria were excluded. 
The following investigations were done. 
At the time of admission, 
Blood sugar 
Blood urea, serum creatinine 
Blood total count, differential count, platelet count 
CPK MB, SGOT, SGPT 
Lipid profile including total cholesterol, LDL, HDL, Triglycerides122 was done 
at admission or within 24 hours. 
On day 4 and 5 fasting glucose was taken and the average was taken as fasting 
glucose111. 
STUDY SAMPLE 
Study sample constitutes the patients who were admitted in ICCU with acute 
STEMI.  85 patients were studied and the criteria for metabolic syndrome were 
applied on these patients. 
STUDY METHODS 
 These patients were divided into two groups  
(1)patients with metabolic syndrome and  
(2) patients without metabolic syndrome. They were followed up during their 
hospital stay. 
The relative influence of each component of metabolic syndrome in both the 
groups and with respect to hospital outcomes and various parameters like 
VT/VF, heart failure, duration of stay in ICCU, recurrent MI, death were 
studied. 
STUDY VARIABLES 
The variables in the study were waist circumference, blood pressure, fasting 
glucose, HDL  and triglycerides. The other variables include hospital outcomes 
like heart failure, ventricular arrhythmias, recurrent MI, length of stay in ICCU 
and case fatality. The following variable like admission glucose ,  total 
cholesterol, LDL cholesterol were also studied. 
 
STATISTICAL ANALYSIS 
All the 85 patients were analysed and criteria for metabolic syndrome were  
applied.Continuous data were expressed as medians and mean +- SD. 
Chi square test was applied to analyse data and to test for significance. All the 
components of metabolic syndrome waist circumference, blood pressure, 
fasting glucose, HDL and Triglycerides have shown a significant p value on 
applying the chi square test. A p value less than 0.05 is statistically significant. 
Apart from this, a significant p value also resulted in heart failure, ICCU stay 
and smoking history. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
RESULTS 
 
PREVALENCE OF METABOLIC SYNDROME IN ACUTE MI 
PATIENTS 
A total of 85 patients with acute STEMI were studied. Of these 42 patients 
fulfilled the criteria for metabolic syndrome. The remaining 43 patients did not 
have metabolic syndrome.                           
Metabolic 
syndrome N Mean 
Std. 
Deviation
No 43 53.58 10.658 
yes 42 56.64 11.155 
The prevalence of metabolic syndrome in acute MI was 49%. This showed the 
high prevalence of metabolic syndrome in acute myocardial infarction patients. 
The mean in the metabolic syndrome group was 56.6 years whereas  in the non-
metabolic syndrome group the mean was 53.5 years. So, the mean age of 
prevalence was found to be high in the MS group. 
PREVALENCE OF METABOLIC SYNDROME – Age group 
 
Met    syn Total     Agegroup 
  no yes   
 20-29 1 1 2
  30-39 2 2 4
  40-49 12 6 18
  50-59 13 14 27
  60-69 13 15 28
  70-79 1 3 4
  80-89 1 1 2
Total 43 42 85
 
The lowest age in the study group was 27 years and the highest age was 86 
years. The incidence of acute myocardial infarction was high in the age group 
between 50-69 years. The prevalence of metabolic syndrome tend to increase 
as age increases, otherwise the incidence of MI is almost similar in both the 
study groups. 
SEX PREVALENCE 
 
Metabolic syndrome 
             NO YES 
 n % n % 
male 4
0
57.1
% 30 42.9%
femal
e 3
20.0
% 12 80.0%
 
Among the 85 acute MI patients studied, 70 patients were male and 15 were 
female. 
Of these, 30 male patients and 12 female patients had metabolic syndrome and 
the other 40 male and 3 female patients did not have metabolic syndrome. 
The study showed that the prevalence of metabolic syndrome in male patients 
and female patients were 42.9% and 80% respectively indicating a higher 
prevalence in the female sex. 
 
 
 
 
 
 
No Metabolic 
syndrome 
Metabolic syndrome Age group 
Male Female Male 
 
Female 
20-29 1 0 1 0 
30-39 2 0 2 0 
40-49 12 0 6 0 
50-59 12 1 9 5 
60-69 12 1 9 6 
70-79 0 1 2 1 
80-89 1 0 1 0 
 
 
The prevalence of  metabolic syndrome tend to increase in both sexes as age 
increases. But the prevalence in age group 50- 70 years in females was more, 
indicating that metabolic syndrome was more prevalent in older age in 
females.i.e., patients with metabolic syndrome were older more likely to be  
women. 
 
The components of metabolic syndrome, abdominal obesity (waist 
circumference), blood pressure,  fasting glucose,  triglycerides were increased  
and  HDL decreased in the metabolic syndrome group. All the five components 
showed statistical significance (p<0.05). 
 
 
Metabolic syndrome 
no yes 
                      components 
  
  n % n % 
Male <90  female <80 38 90.5% 4 9.5%Waist 
Circumferen
ce 
cms 
  
Male >90  female >80 
5 11.6% 38 88.4%
< 130/85 22 73.3% 8 26.7%Blood 
pressure 
Mm Hg  
  
  
>130/85 
 21 38.2% 34 61.8%
< 100 34 89.5% 4 10.5%Fasting 
glucose 
Mg/dL  
>100 9 19.1% 38 80.9%
Male > 40,female > 50 42 57.5% 31 42.5%HDL 
 Mg/dL Male < 40,female < 50 1 8.3% 11 91.7%
<150  36 63.2% 21 36.8%TGL 
 Mg/dL >150 
7 25.0% 21 75.0%
  
 
Parameter Chi-square p value 
Waist circumference  52.85 0.001 
Blood pressure 11.76 0.008 
Fasting glucose 42.57 0.001 
HDL 9.98 0.002 
TGL 10.94 0.001 
 
 
Waist circumference of more than 90 cms in male and > 80 cms in female was 
prevalent in 88.4% of the metabolic syndrome group and it showed statistical 
significance (p=0.001) 
 
 
Hypertension was more prevalent in the metabolic syndrome group (61.8%). 
On applying chi-square test it showed statistical significance (p= 0.008) 
Fasting glucose was prevalent to the extent of 80.9% in the metabolic 
syndrome group and it was statistically significant (p= 0.001). 
To an extent of  91.7% HDL was decreased in the metabolic syndrome group 
and its p value  0.002 was significant. 
Triglycerides were elevated to 75% in the metabolic syndrome group and this 
also showed a significance of p= 0.001. 
The admission glucose was increased in both the groups  (49.3% and 51.7%) 
and this was not statistically significant. The total and LDL cholesterol were 
increased in both the groups and there was no significance in both the groups. 
Only two patients in the study gave a family history of CAHD and they showed 
metabolic syndrome but this was not significant statistically. Though smoking 
was more prevalent in the non-metabolic syndrome group there was statistical 
significance in the metabolic syndrome group (p=0.001). 
 
 
 
 
The various parameters that were studied in both the groups namely patients 
with metabolic syndrome and without metabolic syndrome are tabulated below. 
 
Met syn 
no yes Parameters 
  n % n % 
Admission 
glucose 
<110 5 62.5% 3 37.5%
mg/dL 
  
>110  3
8
49.3
%
3
9 50.7%
<200 1
6
59.3
%
1
1 40.7%
200-239 2
4
50.0
%
2
4 50.0%
Total 
cholesterol 
mg/dL 
>240 3 30.0% 7 70.0%
<100 - - 5 100.0%
100-129 9 40.9%
1
3 59.1%
LDL mg/dL 
  
  
>130 3
4
58.6
%
2
4 41.4%
No 4
3
51.8
%
4
0 48.2%
FH CAHD 
  
yes - - 2 100.0%
No 8 26.7%
2
2 73.3%
smoking 
  
Yes 3
5
63.6
%
2
0 36.4%
No 4
2
51.2
%
4
0 48.8%
Case fatality
  
yes 1 33.3% 2 66.7%
No 3
7
52.1
%
3
4 47.9%
Recurrent 
MI 
  yes 6 42.9% 8 57.1%
No 4
1
53.9
%
3
5 46.1%
VT/VF 
  
yes 2 22.2% 7 77.8%
1 3
2
94.1
% 2 5.9%
Heart failure
Killips class 
  >2 1
1
21.6
%
4
0 78.4%
1 3
7
74.0
%
1
3 26.0%
days CCU 
  
> 1 6 17.1%
2
9 82.9%
 
 
  
 
 
 
Parameter Chi-square p 
value 
Admission 
glucose 
6.86 0.07 
Total cholesterol 2.51 0.28 
LDL cholesterol 7.44 0.02 
FH of CAHD 2.09 0.15 
smoking 10.6 0.001 
Recurrent MI 0.4 0.53 
VT/VF 3.3 0.07 
Heart failure 45.5 0.001 
Case fatality 0.32 0.57 
ICCU Days 27.5 0.001 
 
Though recurrent MI (57.1%) and ventricular arrhythmias (77.8%) were more 
prevalent in the metabolic syndrome they did not  show statistical significance 
in this study. 
Severe heart failure, defined as Killips127 class > =2 was more prevalent in the 
metabolic syndrome group (78.4%) and this was statistically significant 
(p=0.001). 
The stay in ICCU was more in the patients of metabolic syndrome and this was 
also significant (p=0.001). The mean ICCU stay in the metabolic syndrome 
group was 1.8 day whereas it was 1.1 day in the non-metabolic syndrome 
group. 
  
 
 
Group Fasting glucose >100 
mg/dL 
Heart failure >= killips 
class 2 
Metabolic syndrome 40 36 
No metabolic syndrome 9 2 
 
Hyperglycemia was strongly associated with severe heart failure in the 
metabolic syndrome group(90%) when compared to the non-metabolic 
syndrome (22%). 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
DISCUSSION 
 
The metabolic syndrome is a constellation of interrelated risk factors of 
metabolic origin—metabolic risk factors—that appear to directly promote the 
development of atherosclerotic cardiovascular disease (ASCVD).1 So, 
metabolic syndrome  is a risk factor for the development  of coronary artery 
diseases. 
It has variously been referred as the insulin resistance syndrome.  Insulin 
resistance is the key pathologic feature of the syndrome, since its components 
are either causes or consequences of impaired insulin action. 
The constellation of dyslipidemia 
(hypertriglyceridemia and low levels of high-
density lipoprotein cholesterol), elevated blood 
pressure, impaired glucose tolerance, and 
central obesity is identified now as metabolic 
syndrome. It is also a prothrombotic and 
proinflammatory state. Soon, metabolic 
syndrome will overtake cigarette smoking as the 
number one risk factor for heart disease . The 
National Cholesterol Education Program-Adult 
Treatment Panel III1 has identified metabolic 
syndrome as an indication for vigorous lifestyle 
intervention.. 
The predominant underlying risk factors for the syndrome appear to be 
abdominal obesity2–4insulin resistance5,6; other associated conditions can be 
physical inactivity,3,7aging,8 and hormonal imbalance 
The Adult Treatment Panel III of the National Cholesterol Education Program 
(2001, 2005) defined the diagnosis as three or more of the following five 
components 
1. Increased waist circumference (>=102 cm in men and >=88 cm in women), 
indicating central obesity 
2. Elevated triglycerides (>=150 mg/dL or 1.7 mmol/l) 
3. Decreased HDL cholesterol (<40 mg/dL for men, <50 mg/dL for women) 
4. Blood pressure above 130/85 or active treatment for hypertension 
5. Glucose levels above 100 mg/dL or active treatment for hyperglycemia. 
PREVALENCE OF METABOLIC SYNDROME 
 
In this study  metabolic syndrome was highly prevalent (49%) in acute MI 
patients. 
Solymoss BC, Bourassa MG, Campeau L et al on their study on “Effect of 
increasing metabolic syndrome score on atherosclerotic risk profile21 and 
coronary artery disease angiographic severity” have shown an increased 
prevalence of metabolic syndrome ,51% in their study. Similar prevalence rates 
was also shown by Mariam Zeller111 and co workers in their studies. 
The prevalence of metabolic syndrome in coronary artery disease is 51% and 
the number of its metabolic features increases with the severity of angiographic 
coronary artery disease21.The prevalence of metabolic syndrome ranges from 
35% to 80% in patients with hypertension or type 2 diabetes melliltus22,25. 
PREVALENCE  IN VARIOUS AGE GROUPS 
In this study,the prevalence of metabolic syndrome increased as age increases. 
The incidence of acute myocardial infarction was high in the age group 
between 50-69 years. The mean in the metabolic syndrome group was 56.6 
years whereas  in the non-metabolic syndrome group the mean was 53.5 years. 
In a similar study conducted by Marianne Zeller111 and co- workers the mean 
age was 70 years in the western population. Balkau B, Vernay M, Mhamdi L, 
et al in their study “The incidence and persistence of the NCEP  metabolic 
syndrome112” had shown similar features. 
PREVALENCE  IN BOTH SEXES 
Of the 42 metabolic syndrome patients, 30 male patients and 12 female patients 
had metabolic syndrome. It is prevalent in both sexes but the incidence in 
females increases as ages increases than in males. Patients with metabolic 
syndrome were older more likely to be  women.  
 In the Marianne Zeller111 Study, out of 290 metabolic syndrome patients ,108 
patients were female.   Whereas in the non-metabolic syndrome group, females 
constituted 50 out of 343 patients.  
COMPONENTS OF METABOLIC SYNDROME 
 
WAIST CIRCUMFERENCE 
The rationale for the use of waist criteria arises partly from data showing that 
measures of overall obesity, such as body mass index, are relatively insensitive 
indicators of the risk for metabolic and cardiovascular complications of obesity, 
as compared with measures of central or abdominal adiposity.54 Apridonidze 
T54   study on the “Prevalence and characteristics of the metabolic syndrome in 
women with polycystic ovary syndrome”, it has been suggested to use waist 
circumference as an indicator for abdominal obesity. 
Body fat distribution, particularly excess abdominal fat, plays an important role 
in the etiology of the syndrome. 
Waist circumference ( 88.4%) in the metabolic syndrome group was increased 
in the study and it showed statistical significance (p=0.001). In the Zeller study 
111, out of 290 patients of MS group had high waist circumference when 
compared to 94 out of 343 non-MS patients. 
FASTING GLUCOSE 
Increased fasting glucose is seen in patients with metabolic syndrome which is 
shown by studies done by Marianne Zeller111 and co-workers. In their study 55 
out of 290 MS patients had increased fasting glucose in contrast to 20 out of 
343 non-MS patients. 
Fasting glucose was prevalent to the extent of 80.9% in the metabolic 
syndrome group and it was statistically significant (p= 0.001). 
HYPERTENSION 
High blood pressure is a strong risk factor for cardiovascular disease (CVD) 80 
Hypertension is particularly dangerous to the cardiovascular system. This 
concept is supported by the Framingham Heart Study 81. 
Hypertension was more prevalent in the metabolic syndrome group (61.8%). 
On applying chi-square test it showed statistical significance (p= 0.008) which 
is consistent with Zeller111 study which shows 228/290 in the MS group having 
hypertension as that of to 99/343 non-MS patients. 
HYPERTRIGLYCERIDEMIA 
Dyslipidemia is a hallmark of the MetSyn and is characterized by elevated 
triglycerides (TG) and low levels of HDL-C.45.46  Triglycerides were elevated to 
75% in the metabolic syndrome group and this also showed a significance of 
p= 0.001. 
 In the Zeller111 study  elevated triglycerides was found in57% of MS patients 
to that of 14% in the non-MS group. 
LOW HDL 
A low HDL level is another characteristic of atherogenic dyslipidemia 1. To an 
extent of  91.7% HDL was decreased in the metabolic syndrome group and its 
p value=0.002 was significant. So, low HDL is a significant risk factor for 
myocardial infarction as shown by Zeller111 Study,in which 80% in MS group 
and 22% in the non-MS group had myocardial infarction. 
OTHER PARAMETERS 
 
ADMISSION GLUCOSE 
A variety of mechanisms have been proposed whereby hyperglycemia might 
promote atherosclerosis 42. Examples include nonenzymatic glycosylation of 
lipids and proteins, pathogenic effects of advanced glycation products, 
increased oxidative stress, activation of protein kinase C, and microvascular 
disease of the vasa vasorum of the coronary arteries. 
The admission glucose was increased in both the groups  (49.3% and 51.7%) 
and  but this was not statistically significant. But in the Zeller111 study  
admission glucose  was increased in 52% of MS group and 35% of non-MS 
group 
TOTAL CHOLESTEROL AND LDL CHOLESTEROL 
The total and LDL cholesterol were increased in both the groups and there was 
no significance in both the groups which is consistent with Zeller111 study 
SIGNIFICANCE OF FAMILY HISTORY 
Family history of coronary artery disease was defined by a history of premature 
coronary artery disease in first degree relatives ( having occured in those 
relatives at age < 55 years for men and <65 years for women) 
Only two patients in the study gave a family history of  CAHD and they 
showed metabolic syndrome but this was not significant statistically which is 
similar to Zeller111 study. 
HABIT OF SMOKING 
Smoking is a modifiable risk factor. Smokers have increased levels of oxidised  
LDL130, low HDL and increased vascular reactivity.Though smoking was more 
prevalent in the non-metabolic syndrome group(63%)   than metabolic 
syndrome group(36%) there was statistical significance in the metabolic 
syndrome group(p=0.001).  In Zeller111 study also smoking was more prevalent 
in the non- MS group (38%)  than  MS group(23%) and showed statistical 
significance. 
 
 
INFLUENCE OF METABOLIC SYNDROME ON HOSPITAL 
OUTCOMES 
 
HEART FAILURE 
Heart failure was defined as the highest killip class127 reached during 
hospitalisation.Severe heart failure, defined as Killips class > =2 was more 
prevalent in the metabolic syndrome group (78.4%) and this was statistically 
significant (p=0.001). In the Zeller111 study 28% of MS group and 16% of non-
MS group were found to have severe heart failure and this showed significant p 
value<0.001. 
RECURRENT MI,VENTRICULAR ARRHYTHMIAS 
Though recurrent MI (57.1%)and ventricular arrhythmias (77.8%) were more 
prevalent in the metabolic syndrome they did not  show statistical significance 
in this study which is consistent with Zeller111 study. 
Metabolic syndrome did not appear to have an impact on  ventricular 
tachyarrhythmias or recurrent myocardial infarction. 
CASE FATALITY 
Case fatality was high in MS group( 2 patients died) than non MS group( one 
patient died) but this was statistically not significant. In Zeller111 study case 
fatality was 11% in MS group and 4% in non-MS group. 
Metabolic syndrome was associated with an increased case fatality rate though 
it was not an independent predictor of case fatality25,111 
 
ICCU STAY 
The stay in ICCU was more in the patients with metabolic syndrome and this 
was also significant (p=0.001). The mean ICCU stay in the metabolic 
syndrome group was 1.8 day whereas it was 1.1 day in the non-metabolic 
syndrome group. In Zeller111 study the mean ICCU stay in both the groups was 
4 days and it was statistically significant (p=0.03). 
METABOLIC SYNDROME, HYPERGLYCEMIA,  HEART FAILURE 
Hyperglycemia was strongly associated with severe heart failure in the 
metabolic syndrome group(90%) when compared to the non-metabolic 
syndrome (22%). 
There has been a consistent and marked increase in the incidence of heart 
failure in patients with metabolic syndrome.  Among the components of 
metabolic syndrome hyperglycemia is strongly associated with heart failure and 
poor hospital outcomes which is consistent with other studies113-117 
Likewise, low HDL cholesterol and elevated triglyceride levels appeared to 
have little impact on hospital outcomes confirming the data from the Aspirin 
Myocardial Infarction Study111,119 
METABOLIC SYNDROME , A PREDICTOR OF  MYOCARDIAL 
INFARCTION 
In this study, statistically significant results are obtained with regard to the 
components of metabolic syndrome. They are  strongly associated with acute 
myocardial infarction.  
This is consistent with other studies 1,42,45,46,52,53,54,80,111.  Hence, metabolic 
syndrome is a major predictor for acute myocardial infarction. 
 
METABOLIC SYNDROME AND PROGNOSIS 
Large observational studies have shown that heart failure is a major 
determinant of hospital outcomes after acute coronary syndrome 
127,128,129.Hyperglycemia is most strongly associated with  poor outcomes117,126. 
According to the study done by Marianne Zeller111 and co-workers Metabolic 
syndrome is a strong and independent predictor of severe heart failure. Among 
the components of metabolic syndrome hyperglycemia is an independent 
predictor of heart failure . In this study, hyperglycemia has proved to be a  
strong predictor of heart failure. 
Although abdominal obesity undoubtedly plays an important role in insulin 
resistance associated with metabolic syndrome, it does not seem to represent a 
major determinant of outcome111,120. In this study also waist circumference did 
not influence on hospital outcome. 
Wahab et al126 have shown that lipids have no role in predicting hospital 
outcomes which is consistent with this study. 
Hypertension is not a major determinant of mortality and is only a moderate 
predictor of hospital outcome which is in agreement with other 
studies111,118.Even in this study, hypertension had not influenced hospital 
outcomes. 
According to Isomaa et al25, the cardiovascular case fatality rate was markedly 
higher in patients with metabolic syndrome. In this study case fatality( 2 
patients died) was higher in patients with metabolic syndrome though it did not 
show statistical significance. 
According to the study done by Marianne Zeller111 , low HDL has a strong 
association with heart failure  but in this study low HDL  was a strong risk 
factor for acute MI and not for heart failure. 
TREATMENT SIGNIFICANCE 
Among the components of metabolic syndrome hyperglycemia was associated 
more with heart failure. This confirms the importance of evaluating glycemic 
control during the acute phase of MI124. The other components of metabolic 
syndrome are also strong cardiovascular risk factors1and they should be treated. 
 
 
 
 
 
 
 
CONCLUSION 
1. There is a high prevalence of metabolic syndrome in  patients with 
acute myocardial   infarction. 
2. The prevalence of metabolic syndrome increases as age increases 
3. In women, metabolic syndrome is more prevalent in older age. 
4. All the components of metabolic syndrome namely hyperglycemia, 
abdominal obesity,     hypertension, hypertriglyceridemia and low 
HDL levels showed statistical significance (p<0.05) confirming 
strong association with myocardial infarction. 
5. Admission glucose was increased in both the groups and it did not 
show statistical significance with the metabolic syndrome group. 
6. Though, total and LDL cholesterol were increased in both the 
groups,  there was no significance. 
7. Only two patients in the study gave a family history of CAHD and 
they showed metabolic syndrome but this was not significant 
statistically. 
8. Metabolic syndrome group had  a number of cardiovascular risk 
factors and history of previous MI. 
9. Though smoking was more prevalent in the non-metabolic syndrome 
group there was statistical significance in the metabolic syndrome 
group(p=0.001). 
10. Among the components of metabolic syndrome, hyperglycemia was 
associated more with heart failure. This confirms the importance of 
evaluating glycemic control during the acute phase of MI124. 
11. Though recurrent MI (57.1%)and ventricular arrhythmias (77.8%) 
were more prevalent in the metabolic syndrome they did not  show 
statistical significance in this study. 
12. Heart failure was present more in metabolic syndrome group. The 
incidence of heart failure at admission was high and also during 
hospitalisation patients with metabolic syndrome developed severe 
heart failure (killip class > 2). It showed statistical significance. 
13. Hyperglycemia was strongly associated in patients with severe heart 
failure. 
14. Case fatality was high in MS group( 2 patients died) than non MS 
group( one patient died) but this was not statistically significant. 
15. The number of days in ICCU  was high in the MS group when 
compared to NON-MS  group  and it was statistically significant. 
 
 
 
 
LIMITATIONS 
1. Acute metabolic stress due to MI may potentially affect blood 
glucose and lipid      levels121, both of which are criteria for 
metabolic syndrome, and therefore may lead to errors in the 
calculation of the prevalence of metabolic syndrome. However, the 
presence of fasting glycemia111 at days 4 and 5 of AMI  represents a 
valid early marker of individuals at high risk of abnormal glucose 
metabolism. 
2. Moreover, in studies evaluating the biological relevance of lipid 
assessment at the acute phase of MI, a gradual decrease in mean 
HDL cholesterol and triglyceride levels122, 123 during hospital stay 
has been reported but is only minor during the first 24 hours. So, this 
decrease could weakly influence the calculation of the prevalence of 
metabolic syndrome. 
3. Although the risk factors were assessed at the time of index event, 
the duration of risk factors before MI could not be assessed. Hb A1c 
was not studied. 
4. Other tests like microalbuminuria, which is a part of WHO criteria 
for diagnosing metabolic syndrome and a good predictor for 
cardiovascular diseases were not  studied. 
5. The study population was less, only 85 patients were studied. 
Though, statistical significance was obtained for all the components 
of metabolic syndrome. 
6. The study is subject to subject error, 
instrument error and investigator error. 
  
PROFORMA 
CASE STUDY:  PREVALENCE AND IMPACT OF METABOLIC 
SYNDROME ON HOSPITAL OUTCOMES IN ACUTE MYOCARDIAL 
INFARCTION 
 
Name of the patient:                                                      Occup,Address: 
 
Age:                                                                               DOA:            DOD: 
 
Sex:                                                                                Informant: 
                                                    
Presenting complaints:  chest pain – onset,duration,site,character,duration 
                                       Breathlessness 
                                       Palpitations 
                                       Syncope 
 
 
HOPC: 
 
                                                          Yes/No/Duration 
Past H:         CAHD   
                     DM  
                     HT  
Personal H:   Smoking 
                     Alcoholic 
 
Family H: CAHD 
Treatment H: Aspirin, beta blockers, ACE inhibitors, nitrates, statins, OHA. 
 
GENERAL EXAMINATION: 
 
BMI  W/H2 
   
Built                                                                vitals    Temp  
Nutrition                                                                        
Pallor                                                                            PR 
Jaundice 
Cyanosis                                                                       RR 
Clubbing 
Pedal oedema                                                                BP 
Lymphadenopathy 
 
 
 
 
 
 
    
CVS 
 
RS 
  
ABD 
 
CNS 
 
INVESTIGATIONS   
 
ECG 
  
BLOOD TC                                                        CXR 
               DC 
               ESR 
               Hb                                                         
               Platelet count  
 
BLOOD  Urea 
                Sugar 
                S.creatinine 
                S.electrolytes                                        
                Na 
                K 
                Cl 
                HCO3     
                                                                                                                            
SGOT                                                                  
SGPT 
CPK MB 
 
URINE 
Alb 
Sug 
Dep 
Ketones 
 
PRESENTING DATA 
Door to needle time 
PR 
BP 
KILLIPS CLASS 
STEMI- AWMI 
IWMI 
RVMI 
PWMI 
Thrombolytic R/ 
MS CRITERIA 
Waist circumference 
BP 
HDL 
TGL 
Fasting glucose 
MS –yes or no 
 
 
 
 
OUTCOMES 
 
Case fatality 
Non fatal rec. MI 
VT/VF 
 Heart blocks 
Stroke 
HF 
HF > K 1 
Severe HF > k II 
Cardiogenic shock K IV 
ECHO 
Wall motion abnormalities 
LVEF 
Days in ICCU 
 
 
 
DIAGNOSIS 
 
 
 
 
FINAL OUTCOME: 
S. 
no 
IP 
no 
Name ag
e 
se
x 
Wc 
cm 
BP 
Mm Hg
FG 
Mg/d
L 
    HDL
Mg/dL
TGL 
Mg/d
L 
Met 
syn 
TC 
Mg/d
L 
AG 
Mg/d
L 
FH 
CAH
D 
LDL 
Mg/dL 
s
1 136071 Arif khan 60 M 78 110/70 120 41 52 N 183 140 N 132
2 136098 Vijaya kumar 43 M 90 100/70 99 46 84 N 200 120 N 137
3 123364 Chinnathambi 55 M 82 130/90 136 39 178 Y 175 120 N 100
4 136093 Ravikumar 37 M 98 110/80 130 56 172 Y 233 112 N 143
5 136083 Shakunthala 67 F 94 120/80 120 56 218 Y 225 130 N 113
6 136105 Singaram 75 M 70 130/80 170 49 115 Y 200 200 N 121
7 136107 Dharman 48 M 75 110/80 68 56 126 N 233 130 N 152
8 136102 Abdullah 48 M 86 100/80 72 61 99 N 250 132 N 169
9 136106 Sheikh munnar 40 M 80 110/70 160 54 90 N 217 170 N 145
10 136097 Samson 44 M 98 130/90 110 41 93 Y 175 250 Y 115
11 136533 Murugesan 55 M 94 120/70 140 39 210 Y 175 158 N 94
12 136613 Chinnappan 86 M 82 140/90 120 54 98 N 217 160 N 143
13 136109 Madhavan 45 m 101 160/10
0
110 68 102 Y 267 140 N 179
14 136108 Rangamma 68 F 92 130/90 120 56 94 Y 233 138 N 158
15 136100 Rukmani 55 F 97 140/90 120 51 100 Y 208 135 N 137
16 137426 Bahadurkhan 68 M 76 160/10
0
110 46 59 Y 192 130 N 134
17 137432 Mariambee 50 F 87 110/80 130 73 221 Y 292 500 N 175
18 137580 Arunasingh 49 M 95 150/10
0
120 59 148 Y 233 120 N 144
19 136082 Abdul ajeez 54 M 83 120/80 130 44 57 N 192 116 N 137
20 137233 Saifudeen 65 M 91 150/10
0
180 46 142 Y 183 411 N 109
21 136136 Kuttiappan 38 M 83 120/80 130 41 141 N 183 139 N 114
22 136132 Alamelu 60 F 92 160/80 86 49 187 Y 200 154 N 114
23 136898 Elizebeth 50 F 120 130/90 120 54 108 Y 217 171 Y 142
24 136133 Amala 59 F 96 120/80 232 46 102 Y 225 384 N 149
25 136139 Yesudoss 54 M 84 120/80 140 53 107 N 217 130 N 141
26 136138 Kubendran 55 M 94 140/10
0
120 49 160 Y 200 160 N 119
27 136144 Munusamy 46 M 93 130/90 176 63 194 Y 258 96 N 156
28 136148 Saminathan 62 M 84 140/90 98 51 84 N 208 120 N 140
29 136111 Janarthanan 28 M 83 120/80 120 37 72 N 158 110 N 107
30 136118 Vedhachalam 50 M 80 170/12
0
130 41 83 N 183 155 N 225
31 136120 Natarajan 67 M 84 110/80 90 56 88 N 217 136 N 150
32 136142 Papammal 60 F 82 110/70 130 39 185 Y 158 145 N 82
MASTER
APPENDIX- I 
33 136152 Kaurpusamy 53 M 92 140/90 252 54 184 Y 208 134 N 120
34 136143 Jamal 55 M 98 110/80 90 49 122 N 200 112 N 127
35 136117 Madhavan 48 M 78 140/90 90 44 90 N 200 120 N 138
36 136159 Marimuthu 65 M 93 150/80 200 56 122 Y 233 180 N 153
37 136142 Pandian 49 M 88 100/70 96 63 145 N 250 100 N 158
38 134668 Ganesan 45 M 78 150/90 90 41 88 N 167 98 N 108
39 136121 Sajudeen 72 M 100 130/10
0
84 46 158 Y 200 68 N 122
40 136119 Abdul jaffer 62 M 92 130/80 120 56 142 Y 217 136 N 133
41 135839 Kamala 75 F 108 160/10
0
88 46 114 Y 225 110 N 146
42 136160 Selvam 50 M 90 170/11
0
151 66 184 Y 267 180 N 164
43 131592 Sathyanathan 50 M 92 130/10
0
96 39 83 Y 167 90 N 111
44 131129 Vijayan rao 45 M 98 150/90 70 41 132 N 175 68 N 108
45 136162 Kumar 37 M 85 100/80 90 63 111 N 250 160 N 161
46 136143 sakunthala 58 F 92 140/90 120 48 160 Y 218 136 N 146
47 136095 ravikumar 38 M 106 130/90 110 56 172 Y 233 130 N 143
48 130562 Damodharan 63 M 89 120/80 90 54 158 N 175 105 N 100
49 136129 Jayakumar 27 M 94 130/90 128 59 178 Y 250 148 N 169
50 136120 Indrani 64 F 106 160/10
0
130 45 187 Y 267 180 N 152
51 136152 kupusamy 54 M 83 130/90 94 44 57 N 194 116 N 138
52 136126 Ranganathan 48 M 84 120/80 99 41 141 N 184 139 N 114
53 
 
136140 veetabai 70 F 78 150/90 98 48 190 N 233 196 N 153
54 136159 Marimuthu 66 M 83 130/90 90 58 90 N 210 180 N 145
55 136092 Tulasiammal 68 F 78 110/80 96 45 170 N 208 185 N 157
56 136134 Arunachalam 61 M 98 130/80 170 49 156 Y 200 200 N 121
57 136096 Santhanam 54 M 84 130/90 96 54 109 N 218 130 N 142
58 136098 Vijayakumar 44 M 80 110/70 92 54 90 N 218 170 N 142
59 136084 Chandra 58 F 76 110/70 96 55 117 N 235 180 N 158
60 136103 Subramani 53 M 95 120/70 96 59 148 N 233 120 N 144
61 136107 Murugesan 52 M 104 160/10
0
110 68 102 Y 267 140 N 179
62 136114 Thangasamy 54 M 87 130/90 120 51 100 N 192 140 N 137
63 136134 Arunagiri 62 M 102 170/10
0
130 44 190 Y 250 186 N 170
64 136153 Vijayan 43 M 90 100/70 94 46 84 N 200 120 N 137
65 136116 Rajan 55 M 94 120/70 140 39 212 Y 175 148 N 96
66 136124 Munirathinam 64 M 80 130/90 98 54 90 N 220 170 N 148
67 135136 manikumar 66 M 84 140/90 98 51 84 N 208 120 N 140
68 136432 Duraisamy 67 M 86 130/90 96 56 88 N 217 136 N 150
69 136110 Venkataraman 83 M 94 140/10
0
254 56 188 Y 208 138 N 128
70 137429 Mohan 49 M 78 150/90 70 41 132 N 175 68 N 108
71 136148 Saminathan 54 M 88 120/70 90 58 98 N 178 140 N 134
72 136168 Pannerselvam  62 M 84 130/90 98 54 96 N 210 176 N 148
73 136696 Varadharajan 62 M 92 130/90 120 56 142 Y 217 136 N 133
74 137426 Dhanasekaran 58 M 84 130/90 96 58 86 N 208 138 N 148
75 137427 Jayaraman 65 M 78 100/70 90 44 90 N 233 160 N 153
76 136761 Kamaludeen 54 M 87 130/90 96 51 100 N 194 140 N 137
77 136073 Balu 59 M 78 130/90 96 56 98 N 178 140 N 137
78 136091 Shanmugham 66 M 76 120/80 98 54 156 N 175 110 N 135
79 136088 Munusamy 58 M 92 150/10
0
120 48 160 Y 220 139 N 146
80 163089 Narayanasamy 68 M 84 130/90 98 54 108 N 218 130 N 145
81 136086 Murali 64 M 93 140/90 110 54 156 Y 175 135 N 100
82 136087 Mohammed faro 62 M 78 150/90 108 56 142 Y 235 160 N 155
83 136080 chinnadurai 45 M 84 130/90 110 53 140 Y 200 136 N 120
84 136533 Murugesan 50 M 98 140/90 120 37 132 Y 158 110 N 108
85 136079 Shanmugham 68 M 104 150/10
0
138 40 188 Y 238 164 N 160
 
 
KEY FOR MASTER CHART 
 
WC- WAIST CIRCUMFERENCE 
 
BP – BLOOD PRESSURE 
 
FG – FASTING GLUCOSE 
 
TGL – TRIGLYCERIDES 
 
HDL- HIGH DENSITY LIPOPROTEIN 
 
MET SYN – METABOLIC SYNDROME 
 
TC- TOTAL CHOLESTEROL 
 
LDL- LOW DENSITY LIPOPROTEIN 
 
AG- ADMISSION GLUCOSE 
 
FH CAHD- FAMILY HISTORY OF CORONARY ARTERY HEART DISEASE 
 
SM- SMOKING 
 
HF -HEART FAILURE 
 
CF- CASE FATALITY 
 
R MI – RECURRENT MI 
 
VT/VF – VENTRICULAR TACHYCARDIA/VENTRICULAR FIBRILLATION 
 
ICCU – INTENSIVE CORONARY CARE UNIT 
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                                               GLOSSARY 
 
 
 ADA             -   AMERICAN DIABETES ASSOCIATION 
ADMA           -  ASYMMETRICAL DIMETHYL  ARGININE 
AHA              -  AMERICAN HEART ASSOCIATION 
AMI               - ACUTE MYOCARDIAL INFARCTION 
APO B           –  APO LIPOPROTEIN B 
ASCVD         - ATHEROSCLEROTIC CARDIO VASCULAR DISEASE 
ATP III          - ADULT TREATMENT PANEL III 
BMI               – BODY MASS INDEX 
CAD              – CORONARY ARTERY DISEASE 
CAHD           - CORONARY ARTERY HEART DISEASE 
CRP              - C-REACTIVE PROTEIN 
HDL              - HIGH DENSITY LIPOPROTEIN 
HOMA          - HOMEOSTASIS MODEL ASSESSMENT 
ICCU             - INTENSIVE CORONARY CARE UNIT 
IFG                - IMPAIRED FASTING GLUCOSE 
IGT                - IMPAIRED GLUCOSE TOLERANCE 
IHD               - ISCHEMIC HEART DISEASE 
LDL               – LOW DENSITY LIPOPROTEIN 
MS , MET SYN ‐  METABOLIC SYNDROME 
NASH            - NON ALCOHOLIC STEATO HEPATITIS 
NCEP            -NATIONAL CHOLESTEROL EDUCATION PROGRAM 
NEFA            - NON ESTERIFIED FATTY ACID 
NHLBI          - NATIONAL HEART,LUNG, BLOOD INSTITUTE 
NON-MS        -NON METABOLIC SYNDROME 
NON-STEMI – NON ST ELEVATION MYOCARDIAL INFARCTION 
PAI                 - PLASMINOGEN ACTIVATOR INHIBITOR 
SAT               – SUBCUTANEOUS ADIPOSE TISSUE 
STEMI           – ST ELEVATION MYOCARDIAL INFARCTION 
TGL,TG        - TRIGLYCERIDES 
VAT              - VISCERAL ADIPOSE TISSUE 
VF                 – VENTRICULAR FIBRILLATION 
VLDL            - VERY HIGH DENSITY LIPOPROTEIN 
VT                 - VENTRICULAR TACHYCARDIA 
WC                - WAIST CIRCUMFERENCE 
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